行情

CORV

CORV

Correvio Pharma Corp
NASDAQ

实时行情|Nasdaq Last Sale

1.300
-0.860
-39.81%
盘后: 1.370 +0.07 +5.38% 19:59 12/06 EST
开盘
1.400
昨收
2.160
最高
1.710
最低
1.270
成交量
1,496.93万
成交额
--
52周最高
4.440
52周最低
1.270
市值
6,567.78万
市盈率(TTM)
-1.4441
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CORV 新闻

  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Correvio Pharma Corporation  CORV
  • GlobeNewswire.3小时前
  • Mid-Afternoon Market Update: Dow Surges Over 300 Points; Genesco Shares Jump On Upbeat Earnings
  • Benzinga.7小时前
  • TRNX, YEXT, BIG and CGIX among midday movers
  • Seeking Alpha - Article.8小时前
  • Mid-Day Market Update: Crude Oil Rises Over 1%; Yext Shares Fall After Q3 Results
  • Benzinga.9小时前

更多

所属板块

制药
+0.53%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

CORV 简况

Correvio Pharma Corp is a Canada-based specialty pharmaceutical company. It provides brands that meet the needs of acute care physicians and patients. It develops, acquires and commercializes brands for the in-hospital, acute care market segment. The following is its portfolio of approved and marketed brands: Xydalba, for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Brinavess for the conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, as well as Esmocard and Esmocard Lyo, a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Its pipeline of product candidates includes Trevyent, a drug device combination that is designed to deliver treprostinil.
展开

Webull提供Correvio Pharma Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。